160 related articles for article (PubMed ID: 37129769)
1. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
3. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
4. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22.
DiJoseph JF; Popplewell A; Tickle S; Ladyman H; Lawson A; Kunz A; Khandke K; Armellino DC; Boghaert ER; Hamann P; Zinkewich-Peotti K; Stephens S; Weir N; Damle NK
Cancer Immunol Immunother; 2005 Jan; 54(1):11-24. PubMed ID: 15693135
[TBL] [Abstract][Full Text] [Related]
6. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
Shafiee S; Mirzaei R; Salehi M; Jalili N; Taheri A; Farahmand L
Iran J Immunol; 2023 Sep; 20(3):303-315. PubMed ID: 37434357
[TBL] [Abstract][Full Text] [Related]
7. Site-specific and hydrophilic ADCs through disulfide-bridged linker and branched PEG.
Shao S; Tsai MH; Lu J; Yu T; Jin J; Xiao D; Jiang H; Han M; Wang M; Wang J
Bioorg Med Chem Lett; 2018 May; 28(8):1363-1370. PubMed ID: 29559276
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
9. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry.
Sang H; Lu G; Liu Y; Hu Q; Xing W; Cui D; Zhou F; Zhang J; Hao H; Wang G; Ye H
Anal Chim Acta; 2017 Feb; 955():67-78. PubMed ID: 28088282
[TBL] [Abstract][Full Text] [Related]
10. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate.
Luo Q; Chung HH; Borths C; Janson M; Wen J; Joubert MK; Wypych J
Anal Chem; 2016 Jan; 88(1):695-702. PubMed ID: 26629796
[TBL] [Abstract][Full Text] [Related]
11. Native mass spectrometry and ion mobility characterization of trastuzumab emtansine, a lysine-linked antibody drug conjugate.
Marcoux J; Champion T; Colas O; Wagner-Rousset E; Corvaïa N; Van Dorsselaer A; Beck A; Cianférani S
Protein Sci; 2015 Aug; 24(8):1210-23. PubMed ID: 25694334
[TBL] [Abstract][Full Text] [Related]
12. A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells.
Weber T; Mavratzas A; Kiesgen S; Haase S; Bötticher B; Exner E; Mier W; Grosse-Hovest L; Jäger D; Arndt MA; Krauss J
J Immunol Res; 2015; 2015():561814. PubMed ID: 26605343
[TBL] [Abstract][Full Text] [Related]
13. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a camelid single-domain antibody directed to human CD22 biomarker.
Faraji F; Tajik N; Behdani M; Shokrgozar MA; Zarnani AH; Shahhosseini F; Habibi-Anbouhi M
Biotechnol Appl Biochem; 2018 Sep; 65(5):718-725. PubMed ID: 29543347
[TBL] [Abstract][Full Text] [Related]
15. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
16. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
Beerli RR; Hell T; Merkel AS; Grawunder U
PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
[TBL] [Abstract][Full Text] [Related]
17. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes.
Wakankar AA; Feeney MB; Rivera J; Chen Y; Kim M; Sharma VK; Wang YJ
Bioconjug Chem; 2010 Sep; 21(9):1588-95. PubMed ID: 20698491
[TBL] [Abstract][Full Text] [Related]
18. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft.
Hartimath SV; El-Sayed A; Makhlouf A; Bernhard W; Gonzalez C; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
Oncotarget; 2019 Feb; 10(10):1031-1044. PubMed ID: 30800216
[TBL] [Abstract][Full Text] [Related]
20. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
